• Novartis defends Zolgensma in face of FDA’s data concerns pharmaceutical-technology
    August 08, 2019
    The US Food and Drug Administration (FDA) has issued a statement regarding data accuracy issues related with Novartis’ biologic license application (BLA) for gene therapy Zolgensma (onasemnogene abeparvovec-xioi).
PharmaSources Customer Service